ICAM1 and systemic sclerosis: Further on, 7/20 SSc-ILD patients with respiratory symptoms were therapy naïve and they had significantly increased levels of only ICAM1 + EVs compared to those on immunosuppressive therapy [81.3 (6.5–175.0) vs. 10.6 (2.1–71.3, p = 0.006)].